免疫療法の分野における最近の重要な進歩によって、複数の異なる形態の疾患に対するいくつかの新しい治療アプローチの決定には、多くの課題が残っています。がんなどの一部の疾患における医薬品開発の有望な可能性を秘めていることが判明している新しい標的の 1 つが SYK です。脾臓チロシンキナーゼ (SYK) は、細胞質の非受容体キナーゼであり、発癌特性を持つことが明らかになり、それ以来長期に渡って研究されてきました。その治療の可能性は製薬会社によって注目されており、SYK に対する薬剤は初期の臨床試験フェーズを開始しています。
目次
1. Introduction To Spleen Tyrosine Kinase (Syk)
1.1 Overview of Syk Protein
1.2 Structure of Syk Protein
1.3 Potential Of Syk As Drug Target
2. Syk Inhibitors - Mechanism Of Action
3. Role Of Syk Inhibitors By Indication
3.1 Cancer
3.2 Autoimmune diseases
3.3 Viral Infections
3.4 Cardiovascular Diseases
4. Fostamatinib (Tavalisse) - 1st Approved Syk Inhibitor
4.1 Overview and Patent Analysis
4.2 Pricing and Dosage Analysis
4.3 Sales Analysis (2018 - 2022)
5. Global Syk Inhibitors Market Analysis
5.1 Current Market Scenario
5.2 Syk Inhibitors Market Future Outlook (2023 -2028)
6. Global Syk Inhibitors Clinical Pipeline Overview
6.1 By Country
6.2 By Indication
6.3 By Organization
6.4 By Phase
7. Global Syk Inhibitors Clinical Pipeline By Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-III
8. Marketed Syk Inhibitors Clinical and Patent Insight
9. Global Syk Inhibitors Market Dynamics
9.1 Market Drivers
9.2 Market Restraints
10. Competitive Landscape
10.1 Calithera Biosciences
10.2 CrystalGenomics
10.3 CSPC Ouyi Pharmaceutical
10.4 Genosco
10.5 Hanmi Pharmaceutical
10.6 HUTCHMED
10.7 IACTA Pharmaceuticals
10.8 Kronos Bio
10.9 Libertas Bio
10.10 Oscotec
10.11 Rigel Pharmaceuticals
10.12 Takeda Oncology
List of Figures & Tables
Figure 1-1: Syk - History and Discovery
Figure 1-2: Syk - Structure Of Protein
Figure 4-1: Fostamatinib - Approval Year By Country/Region
Figure 4-2: Fostamatinib - Patents Overview
Figure 4-3: US - Price for 60 tablets and Price Per Unit of 100 mg and 150 mg Fostamatinib Doses (US$), February’2023
Figure 4-4: EU - Price for 60 tablets and Price Per Unit of 100 mg Fostamatinib Dose (US$), February’2023
Figure 4-5: EU - Price for 60 tablets and Price Per Unit of 150 mg Fostamatinib Dose (US$), February’2023
Figure 4-6: Tavalisse - Initial and Increased Dose for the Treatment of Chronic Immune Thrombocytopenia (mg)
Figure 4-7: Global - Fostamatinib Sales (US$ Million), 2018-2022
Figure 4-8: Global - Fostamatinib Quarterly Sales (US$ Million), 2022
Figure 4-9: Fostamatinib - Cost of Product Sales (US$ ‘000), 2018-2022*
Figure 4-10: Fostamatinib - Cost of Product Sales (US$ ‘000), Q1-Q3’2022
Figure 4-11: Global - Total Fostamatinib Bottles Shipped, 2020-2022
Figure 4-12: Global - Total Fostamatinib Bottles Shipped, 2022
Figure 5-1: Global - Syk Inhibitor Drug Market (US$ Million), 2018-2022
Figure 5-2: Global - Syk Inhibitor Drug Market (US$ Million), Q1 - Q4’2022
Figure 5-3: Global - Syk Inhibitor Drug Market (US$ Million), 2023-2028
Figure 6-1: Global - Number Of Syk Inhibitors Clinical Trials By Country, 2023 Till 2028
Figure 6-2: Global - Number Of Syk Inhibitors Clinical Trials By Indication, 2023 Till 2028
Figure 6-3: Global - Number Of Syk Inhibitors Clinical Trials By Organization, 2023 Till 2028
Figure 6-4: Global - Number Of Syk Inhibitors Clinical Trials By Phase, 2023 Till 2028
Figure 9-1: Syk Inhibitors Market Drivers
Figure 9-2: Syk Inhibitors Market Challenges
